Estrella Immunopharma, Inc. quarterly report, Q3 FY2021

Vollständiges Dokument

Filing summary

Registrant discrepancy: The supplied filing is TradeUP Acquisition Corp.’s Form 10-Q, not a filing identified as Estrella Immunopharma, Inc. This summary reflects the filing text provided. The report was filed for the quarter ended September 30, 2021 and signed November 10, 2021.

Business context and reporting period

TradeUP was a newly formed blank-check company seeking a business combination. As of September 30, it had not begun operations, selected a target, or initiated substantive discussions with a target. It completed its IPO in July 2021. The financial statements cover the three months ended September 30 and, for certain statements, the period from inception on January 6, 2021 through September 30.

Financial position and results

  • Revenue and profit: No operating revenue. Third-quarter net loss was $107,547; net loss from inception was $111,921. Operating costs included $97,600 of franchise tax expense for both reported periods. No income tax provision was recorded.
  • Per-share results: Third-quarter basic and diluted loss per share for non-redeemable common stock was $0.99. Redeemable shares showed income per share of $0.33, reflecting the allocation and accretion accounting described in the filing. Inception-to-date figures were a $2.06 loss per non-redeemable share and $1.78 income per redeemable share.
  • Cash flow: From inception through September 30, operating cash use was $22,858, investing cash use was $45.186 million, and financing provided $45.981 million. Cash at period-end was $772,168. The filing does not provide a comparable prior-year period.
  • Assets and liquidity: Total assets were $45.967 million, including $45.187 million in the Trust Account and $772,168 of cash outside the trust. Trust funds were restricted principally for a business combination or public-share redemptions. Management said available working capital and borrowing capacity should meet needs through the earlier of a business combination or one year from filing.
  • Liabilities and debt: Total liabilities were $1.651 million, including $100,600 of current liabilities and $1.551 million of deferred underwriters’ marketing fees payable upon a business combination. No long-term debt or working-capital loans were outstanding at quarter-end; the $300,000 sponsor promissory note had been repaid.
  • Margins: Not meaningful because the company had no operating revenue.

Changes, outlook, and risks

  • The company raised $44.3 million in its IPO and $3.122 million through private-placement shares, and placed $45.186 million in the Trust Account. It also reported $2.215 million public warrants outstanding.
  • There was no operating guidance or identified acquisition target. The company had 18 months from the IPO closing to complete a business combination; otherwise, it was required to redeem public shares and liquidate, subject to the filing’s terms. Warrants would expire worthless if no business combination were completed.
  • The filing revised prior financial statements to classify all redeemable public shares as temporary equity and record accretion to redemption value. Management deemed the prior classification error immaterial. Disclosure controls were reported ineffective as of September 30 because of the correction; management described planned accounting training and enhanced review.
  • Management noted that COVID-19 could adversely affect the company’s financial position, operations, or target search, although the impact was not determinable. The filing also disclosed that approximately $522,000 of cash exceeded the FDIC insurance limit.
  • No material legal proceedings, defaults on senior securities, or material changes to previously disclosed risk factors were reported. The filing states there were no material subsequent events.

Investor verification priorities

  1. Confirm the issuer: the provided document names TradeUP Acquisition Corp., not Estrella Immunopharma, Inc.
  2. Review the temporary-equity revision, its stated immateriality, and the ineffective-controls disclosure.
  3. Verify the trust balance, redemption terms, and the 18-month business-combination deadline measured from the IPO closing.
  4. Assess whether the $772,168 of unrestricted cash and potential sponsor financing were adequate for search and transaction costs.
  5. Check the deferred $1.551 million underwriters’ fee and the consequences for public shareholders and warrants if no transaction closes.